Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?

European Journal of Endocrinology

Volumn 155, Issue 5, 2006, Pages 717-723

  de Herder, Wouter W ^a   Reijs, Ambroos E M ^a   Feelders, Richard A ^a   van Aken, Maarten O ^a   Krenning, Eric P ^a   Tanghe, Hervé L J ^a   van der Lely, Aart Jan ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDEPRIDE; IODINE 123; QUINAGOLIDE;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG UPTAKE; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; IN VIVO STUDY; LONG TERM CARE; MALE; MOLECULAR IMAGING; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDING; STATISTICAL SIGNIFICANCE; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT DURATION; TUMOR VOLUME;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; BENZAMIDES; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PYRROLIDINES; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33845276774     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02281     Document Type: Article

References (46)

1. Greenman Y & Melmed S. Diagnosis and management of nonfunctioning pituitary tumors. Annual Review of Medicine 1996 47 95-106.
2. Snyder PJ. Gonadotroph cell pituitary adenomas. Endocrinology and Metabolism Clinics of North America 1987 16 755-764.
3. Snyder PJ. Gonadotroph cell adenomas of the pituitary. Endocrine Reviews 1985 6 552-563.
4. Ebersold MJ, Quast LM, Laws ER, Jr, Scheithauer B & Randall RV. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. Journal of Neurosurgery 1986 64 713-719.
5. Comtois R, Beauregard H, Somma M, Serri O, Aris-Jilwan N & Hardy J. The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 1991 68 860-866.
6. Harris PE, Afshar F, Coates P, Doniach I, Wass JA, Besser GM & Grossman A. The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary tumours. Quarterly Journal of Medicine 1989 71 417-427.
7. Bradley KM, Adam CB, Potter CP, Wheeler DW, Anslow PJ & Burke CW. An audit of selected patients with non-functioning pituitary adenoma treated by transsphenoidal surgery without irradiation. Clinical Endocrinology 1994 41 655-659.
8. Turner HE, Stratton IM, Byrne JV, Adams CB & Wass JA. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clinical Endocrinology 1999 51 281-284.
9. Snyder PJ, Fowble BF, Schatz NJ, Savino PJ & Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas. American Journal of Medicine 1986 81 457-462.
10. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS & Baik JH. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Molecular and Cellular Endocrinology 2003 206 49-62.
11. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R & Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 2001 14 329-336.
12. Lamberts SW, Verleun T, Oosterom R, Hofland L, van Ginkel LA, Loeber JG, van Vroonhoven CC, Stefanko SZ & de Jong FH. The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro. Journal of Clinical Endocrinology and Metabolism 1987 64 524-530.
13. Serri O, Marchisio AM, Collu R, Hardy J & Somma M. Dopaminergic binding sites in human pituitary adenomas other than prolactinomas. Hormone Research 1984 19 97-102.
14. Bevan JS & Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clinical Endocrinology 1986 25 561-572.
15. Klibanski A, Shupnik MA, Bikkal HA, Black PM, Kliman B & Zervas NT. Dopaminergic regulation of alpha-subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1988 66 96-102.
16. D'Emden MC & Harrison LC. Rapid improvement in visual field defects following bromocriptine treatment of patients with non-functioning pituitary adenomas. Clinical Endocrinology 1986 25 697-702.
17. Vance ML, Ridgway EC & Thorner MO. Follicle-stimulating hormone-and alpha-subunit-secreting pituitary tumor treated with bromocriptine. Journal of Clinical Endocrinology and Metabolism 1985 61 580-584.
18. Grossman A, Ross R, Charlesworth M, Adam CB, Wass JA, Doniach I & Besser GM. The effect of dopamine agonist therapy on large functionless pituitary tumours. Clinical Endocrinology 1985 22 679-686.
19. van Schaardenburg D, Roelfsema F, van Seters AP & Vielvoye GJ. Bromocriptine therapy for non-functioning pituitary adenoma. Clinical Endocrinology 1989 30 475-484.
20. Nobels FR, de Herder WW, van Den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J, de Jong FH & Lamberts SW. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. European Journal of Endocrinology 2000 143 615-621.
21. Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews 1992 13 220-240.
22. Wollesen F, Andersen T & Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Annals of Internal Medicine 1982 96 281-286.
23. Kwekkeboom DJ & Lamberts SW. Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma. Clinical Endocrinology 1992 36 171-176.
24. de Bruin TW, Kwekkeboom DJ, van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW & Croughs RJ. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. Journal of Clinical Endocrinology and Metabolism 1992 75 1310-1317.
25. Renner U, Mojto J, Lange M, Muller OA, Von Werder K & Stalla GK. Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 1994 130 80-91.
26. Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider-Groswasser II, Segev Y, Ouaknine G & Stern N. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clinical Endocrinology 2005 63 39-44.
27. Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L & Lombardi G. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 2004 89 1674-1683.
28. Pirker W, Brucke T, Riedl M, Clodi M, Luger A, Asenbaum S, Podreka I & Deecke L. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors. Journal of Neural Transmission. General Section 1994 97 235-244.
29. Pirker W, Riedl M, Luger A, Czech T, Rossler K, Asenbaum S, Angelberger P, Kornhuber J, Deecke L, Podreka I & Brucke T. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. Journal of Nuclear Medicine 1996 37 1931-1937.
30. de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP & Lamberts SW. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand. Clinical Endocrinology 1996 45 755-767.
31. de Herder WW, Reijs AEM, de Swart J, Kaandorp Y, Lamberts SWJ, Krenning EP & Kwekkeboom DJ. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas. European Journal of Nuclear Medicine 1999 26 46-50.
32. de Herder WW, Kwekkeboom DJ, Reijs AEM, Kooy PPM, Hofland LJ, Krenning EP & Lamberts SW. Receptor scintigraphy with somatostatin analogues and dopamine antagonists of pituitary tumours. In Pituitary Adenomas. From Basic Research to Diagnosis and Therapy, pp 93-104. EdsK Von Werder & R Fahlbusch, Amsterdam: Elsevier Science, BV, 1996.
33. Kwekkeboom DJ, de Herder WW & Krenning EP. Receptor imaging in the diagnosis and treatment of pituitary tumors. Journal of Endocrinological Investigation 1999 22 80-88.
34. 123I-methoxybenzamide. Clinical Endocrinology 2000 52 437-445.
35. 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 248-252.
36. Petrossians P, de Herder W, Kwekkeboom D, Lamberigts G, Stevenaert A & Beckers A. Malignant prolactinoma discovered by D2 receptor imaging. Journal of Clinical Endocrinology and Metabolism 2000 85 398-401.
37. Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl F, Muller A, Lange M, Weindl A & Stalla GK. Heterogeneous dopamine D2 receptor subtype messenger ribonuclelc acid expression in clinically nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1368-1375.
38. Lania A, Reza-Flahi F, Gil-del-Alamo P, Saccomanno K, Mantovani S & Spada A. Abnormal transduction of dopamin signal in human nonfunctioning pituitary adenomas. Journal of Endocrinological Investigation 1995 18 265-270.
39. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ & Lamberts SW. Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 2452-2462.
40. Ivan G, Szigeti-Csucs N, Olah M, Nagy GM & Goth MI. Treatment of pituitary tumors: dopamin agonists. Endocrine 2005 28 101-110.
41. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R & Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. New England Journal of Medicine 2003 349 2023-2033.
42. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002 5 55-65.
43. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS & Klibanski A. Primary medical therapy of micro-and macropro-lactinomas in men. Journal of Clinical Endocrinology and Metabolism 2000 85 3053-3057.
44. Casulari LA, Naves LA, Mello PA, Pereira NA & Papadia C. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Hormone Research 2004 62 300-305.
45. Petrossians P, Ronci N, Valdes-Socin H, Kalife A, Stevenaert A, Bloch B, Tabarin A & Reckers A. ACTH silent adenoma shrinking under cabergoline. European Journal of Endocrinology 2001 144 51-57.
46. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G & Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. Journal of Endocrinological Investigation 1999 22 860-865.